FAKTOR-OPTIONSSCHEIN - INCYTE CO. Stock

DE000SQ0GMX3

Delayed Deutsche Boerse AG 07:12:00 2024-05-20 EDT
0.81 ^EUR	-3.57%

Current month	+44.83%
1 month	+29.23%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart INCYTE CORPORATION

Latest news about INCYTE CORPORATION

Transcript : Incyte Corporation Presents at Bank of America Health Care Conference 2024, May-15-2024 08:00 AM	05-15
Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress	05-14	BU
Equities Close Mixed as Markets Weigh Consumer Inflation Survey	05-13	MT
Equities Close Mixed as Markets Parse Consumer Inflation Survey	05-13	MT

More news

Quotes 5-day view

Date	Price	Change
24-05-20	0.81	-3.57%
24-05-17	0.84	+2.44%
24-05-16	0.82	-2.38%
24-05-15	0.84	-1.18%
24-05-14	0.85	-3.41%

Delayed Quote Deutsche Boerse AG

Last update May 20, 2024 at 07:12 am

More quotes

Static data

Product type	Exotic Products
Buy / Sell	CALL
Underlying	INCYTE CORPORATION
Issuer	Société Générale
WKN	SQ0GMX
ISIN	DE000SQ0GMX3
Date issued	2022-09-16
Strike	68.42 $
Maturity	Unlimited
Parity	1 : 1
Emission price	10.16 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	22.36 €
Lowest since issue	0.49 €
Spread	0.06 €
Spread %	6.90%

Company Profile

Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (85.6%); - royalties (14.2%); - income from research and cooperation agreements (0.2%).

Sector

More about the company

Ratings for Incyte Corporation

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Consensus: Incyte Corporation

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

57.1 USD

Average target price

73.35 USD

Spread / Average Target

+28.46%

Consensus